Change in gene may be underlying molecular defect in some colorectal cancers, study suggests

September 20, 2005

Inactivation of a DNA repair gene may be an early step in the development of sporadic colorectal tumors, and detection of the molecular basis for this inactivation may ultimately be useful in risk assessment for colorectal cancer, according to a new study in the September 21 issue of the Journal of the National Cancer Institute.

Cancers can arise from a region of cells with a "field defect", cells that appear normal but that have an underlying molecular defect. The molecular basis for the field defect is easy to understand when tumors develop from cells that all have similar genetic abnormalities, such as those that occur in patients who are genetically predisposed to a cancer or those who undergo an exposure to a carcinogen such as tobacco smoke. However, how the field defect may arise in most sporadic cancers in unclear.

In colorectal cancer, the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is often methylated--that is, the gene's promoter region has methyl groups added to it, which inactivate the gene. Jean-Pierre J. Issa, M.D., of the University of Texas M. D. Anderson Cancer Center in Houston, and colleagues hypothesized that MGMT promoter methylation could be one of the characteristics of the field defect in colorectal cancer, so they studied MGMT promoter methylation in the tumor, adjacent mucosa, and nonadjacent mucosa of 95 colorectal cancer patients and in the colon mucosa of 33 subjects without cancer.

MGMT promoter methylation was found in 50% to 94% of colorectal tumors, depending on the method of detection, and normal-appearing colon mucosa up to 10 cm away from the tumor had detectable MGMT methylation. In addition, the authors detected MGMT methylation in the normal colon mucosa of several subjects who did not have cancer.

"Because a loss of MGMT protein function is a plausible predisposing factor for cancer through the increased occurrence of mutations..., our data indicate that MGMT promoter methylation may qualify as a marker of the field defect in colorectal cancer," the authors write. In addition, "given the high lifetime risk of colorectal tumor development in the U.S. population, it is reasonable to propose testing to determine whether healthy persons with MGMT promoter methylation in normal colorectal mucosa are at higher risk of developing a colon tumor than those without such methylation."

In an editorial, Edward Giovannucci, M.D., Sc.D., of the Harvard School of Public Health, and Shuji Ogino, of Brigham and Women's Hospital, both in Boston, review the concept of the field defect (also called the field effect or field cancerization). They also raise several questions about how these findings may affect related areas of research, such as approaches to chemoprevention and "whether the reversal of DNA methylation in precancerous cells may prevent the development of new primary cancers in the same organ," they write.
-end-
Contacts:
  • Article: Laura Sussman, Communications Office, M. D. Anderson Cancer Center, 713-745-2457, lsussman@mdanderson.org
  • Editorial: Edward Giovannucci, Harvard School of Public Health, egiovann@hsph.harvard.edu

    Citations:
  • Article: Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, et al. MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer. J Natl Cancer Inst 2005;97:1330-8.
  • Citation: Giovannucci E, Ogino S. DNA Methylation, Field Effects, and Colorectal Cancer. J Natl Cancer Inst 2005;97:1317-9.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

    Journal of the National Cancer Institute

    Related Cancer Articles from Brightsurf:

    New blood cancer treatment works by selectively interfering with cancer cell signalling
    University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

    UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
    A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

    Breast cancer treatment costs highest among young women with metastic cancer
    In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

    Cancer mortality continues steady decline, driven by progress against lung cancer
    The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

    Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
    Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

    Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
    The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

    Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
    Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

    More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
    An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

    New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
    Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

    American Cancer Society outlines blueprint for cancer control in the 21st century
    The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

    Read More: Cancer News and Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.